Optimer Pharmaceuticals, Inc. (OPTR)

[oldberkeley]

I seriously expect pps to be close to $20 early June after approval is granted. The potential to kill c-diff with far less relapse rates compared to current standard care is big.

I'm long OPTR and fully expect FDA approval.

IMO $20 is way too optimistic, $15'ish is more like it.

Remember that the panel voted 6-7 NO on the crucial question of recurrence benefit. In fairness, perhaps that was simply because OPTR got greedy and asked for too much; instead of "prevention of recurrence" something like "reduction in the risk of recurrence" would have been more acceptable to the panel.

Whatever the answer, it's an important factor to consider. No doubt the company has been negotiating with the FDA about the exact label language, and hopefully we get at least "30-day recurrence superiority."

Best of luck to all.